**Author details**

Kunihiro Sakuma Institute for Liberal Arts, Environment and Society, Tokyo Institute of Technology, Tokyo, Japan

\*Address all correspondence to: sakuma@ila.titech.ac.jp

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**5**

*Introductory Chapter: Muscular Dystrophy and Recent Therapeutic Strategy*

[9] Quattrocelli M, Barefield DY, Warner JL, Vo AH, Hadhazy M, Earley JU, et al. Intermittent glucocorticoid steroid dosing ehnahces muscle repair without eliciting muscle atrophy. Journal of Clinical Investigation.

[10] Kalra S, Montanaro F, Denning C. Can human pluripotent stem cellderived cardiomyocytes advances understanding of muscular sydtrophies? Journal of Neuromuscular Diseases.

[11] Salmaninejad A, Valilou SF, Bayat H, Ebadi N, Daraei A, Yousefi M, et al. Duchenne muscular dystrophy: An updated review of common available therapies. The International Journal of Neuroscience. 2018;**128**(9):854-864

[12] Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hipsC-derived muscle cells. Cell Stem

Cell. 2016;**18**(4):533-540

2017;**127**(6):2418-2432

2016;**3**(3):309-332

*DOI: http://dx.doi.org/10.5772/intechopen.86709*

[1] Vainzof M, Ayub-Guerrieri D, Onofre PC, Martins PC, Lopes VF, Zilberztajn D, et al. Animal models for genetic neuromuscular disease. Journal of Molecular Neuroscience.

[2] Carnio S, LoVerso F, Baraibar MA, Longa E, Khan MM, Maffei M, et al. Autophagy impairment in muscle induces neuromuscular junction

degeneration and precocious aging. Cell

Reports. 2014;**8**(5):1509-1521

[3] Sakuma K, Kinoshita M, Ito Y, Aizawa M, Aoi W, Yamaguchi A. p62/ SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice. Journal of Cachexia, Sarcopenia and Muscle.

[4] De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M, et al. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death & Disease. 2012;**3**:e418

[5] Sakuma K, Aoi W, Yamaguchi A. The intriguing regulators of muscle mass in sarcopenia and muscular dystrophy. Frontiers in Aging Neuroscience.

[6] Sakuma K, Aoi W, Yamaguchi A. Molecular mechanism of sarcopenia and cachexia: Recent research advances. Pflügers Archiv/European Journal of Physiology. 2017;**469**(5-6):573-591

[7] Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve. 2017;**55**(4):458-464

[8] Ciafaloni E, Moxley RT. Treatment options for Duchenne muscular dystrophy. Current Treatment Options

in Neurology. 2008;**10**(2):86-93

**References**

2008;**34**(3):241-248

2016;**7**(2):204-212

2013;**6**:230

*Introductory Chapter: Muscular Dystrophy and Recent Therapeutic Strategy DOI: http://dx.doi.org/10.5772/intechopen.86709*
